Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Research analysts at Zacks Research lifted their Q1 2024 earnings per share estimates for Allogene Therapeutics in a report issued on Tuesday, February 6th. Zacks Research analyst S. Ganoria now expects that the company will earn ($0.48) per share for the quarter, up from their prior forecast […]